Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247 on ClinicalTrials.gov · last registry update 2026-08-17

Recruiting now, toward 60 participants. Due to report 9 April 2028, alongside 31 other tracked readouts that quarter. Primary outcome, as filed: Changes in the 10-year risk of cardiovascular disease. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: City of Hope Medical Center
Sponsor type: Other
Enrollment: 60
Started: 2025-11-05
Primary completion: 2028-04-09 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in the 10-year risk of cardiovascular disease

Conditions studied

Prostate Carcinoma · Recurrent Prostate Carcinoma

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.